Conclusions Metabolites associated with the NAD + pathway may be dysregulated in the skin of patients with CLE. Available treatments including nicotinamide supplementation and anti-CD38 biologics that ...

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies ...

强生达雷妥尤单抗进入“百亿美元俱乐部”几乎已无悬念之际，蓄势已久的CD38药物终于在2025年开年展现出了燎原态势。 2025年的第二周，CD38靶点 ...

1月10日，康诺亚宣布，就潜在同类最优的靶向CD38人源化单克隆抗体CM313与Timberlyne Therapeutics达成独家授权许可协议。 CM313是由康诺亚自主研发的靶向 ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...

每经AI快讯，1月9日，据赛诺菲中国微信公众号消息，赛诺菲今日宣布，旗下抗CD38单抗赛可益（艾沙妥昔单抗注射液）获得国家药品监督管理局（NMPA ...

赛诺菲1月9日宣布，旗下抗cd38单抗赛可益（艾沙妥昔单抗注射液）获得国家药品监督管理局批准，用于与泊马度胺和地塞米松联合用药，治疗既往 ...

NAD+ is important for DNA repair, mitochondrial function, cell proliferation, lipid and glucose homeostasis, and immune cell function. Several NAD+-dependent enzymes, including sirtuins, CD38, and ...